When was Msics Pharma founded?

Msics Pharma was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is Msics Pharma located?

Msics Pharma is headquartered in Tel Aviv, Israel.

How many employees does Msics Pharma have?

As of Sep 30, 2026, the latest employee count at Msics Pharma is 8.

Is Msics Pharma a funded company?

Msics Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on May 05, 2026.

When was the latest funding round of Msics Pharma?

Msics Pharma's latest funding was a $***** Series A round on May 05, 2026, with participation from 4 investors.

Where does Msics Pharma rank among its competitors?

Msics Pharma ranks 25th amongst 37 active competitors, of which 10 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Psilera, which secured $8.8M in May, 2026.

Who are the top competitors of Msics Pharma?

Msics Pharma's top competitors include COMPASS Pathways, MindMed and Gilgamesh. Among them, Psilera secured the most recent funding round in May, 2026.

Msics Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of naturally-sourced psilocybin products for pharmaceutical applications and clinical trials. The company operates a production facility producing a flagship psilocybin product. This product is undergoing trials to treat medical conditions. The company is recruiting patients for clinical trials in depression, OCD, anorexia, and PTSD.

Key Metrics

Founded Year

2020

Location

Tel Aviv, Israel

Stage

Series A

Total Funding

$3.6M in 1 round

Latest Funding Round

Series A, May 05, 2026, $*****

Investors

FUSION & 5 more

Ranked

25^th among 37 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

COMPASS Pathways & 43 more

View Msics Pharma's full profile

Msics Pharma has raised a total funding of $3.6M over 1 round. Its latest funding round was a Series A round on May 05, 2026 for $*****. 4 investors participated in its latest round. Msics Pharma has 4 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Msics Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 05, 2026	5790145	Series A	1797855	8493080	6663322	1465253

Access funding benchmarks and valuations. Sign up today!

View details of Msics Pharma's funding rounds and investors

The founders of Msics Pharma is Omer Zerahia.

Here are the details of Msics Pharma's key team members:

Omer Zerahia: Co-Founder of Msics Pharma and founder of 1 other company.

View details of Msics Pharma's Founder profiles and Board Members

Msics Pharma's employee count trend

Msics Pharma has 8 employees as of Sep 26. Here is Msics Pharma's employee count trend over the years:

Uncover Msics Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Msics Pharma include COMPASS Pathways, MindMed and Gilgamesh. Here is the list of Top 10 competitors of Msics Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Perceptive Advisors, Able Partners & 20 others	68/100
2nd	MindMed 2019, New York City (United States), Public	Developer of psychedelic-based therapies for brain health disorders	-	TR Ventures, K2 HealthVentures & 9 others	58/100
3rd	Gilgamesh 2019, New York City (United States), Series B	Developer of drugs for neuropsychiatric conditions	$152M	Prime Movers Lab, Satori Capital & 18 others	58/100
4th	Cybin 2002, Toronto (Canada), Public	Provider of psychedelic therapeutics for psychiatric disorders	-	Hightrailcapital, Subversive Capital & 10 others	56/100
5th	Delix Therapeutics 2019, Menlo Park (United States), Series A	Developer of therapeutic solutions for the treatment of multiple neurological disorders	$100M	RA Capital Management, Artis Ventures & 22 others	57/100
6th	Psilera 2019, Tampa (United States), Seed	Manufacturer of natural-based medicines for the treatment of mental health illnesses	$11.3M	Iter Investments, What If Ventures & 4 others	50/100
7th	Tryp Therapeutics 2020, Kelowna (Canada), Public	Developer of therapeutic solutions for treating neuropsychiatric disorders & pain	-	-	44/100
8th	Neural Therapeutics 2020, Toronto (Canada), Public	Developer of ethnobotanical drug for neurological disorder	$495K	-	47/100
9th	Psyence 1997, Toronto (Canada), Public	Developer of psychedelic therapeutics for mental health disorders	-	-	44/100
10th	Eleusis 2013, London (United Kingdom), Acquired	Developer of immunomodulatory and neuroprotective medicines	$1.47M	Palo Santo, Noetic Psychedelic Fund & 4 others	44/100
25th	Msics Pharma 2020, Tel Aviv (Israel), Series A	Developer of naturally-sourced psilocybin products for pharmaceutical applications and clinical trials	$3.6M	GlenRock Israel, FUSION & 4 others	29/100